We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
TCN, an AKT inhibitor, exhibits potent antitumor activity and enhances radiosensitivity in hypoxic esophageal squamous cell carcinoma in vitro and in vivo.
- Authors
QING GUO; JIA HE; FENG SHEN; WEI ZHANG; XI YANG; CHI ZHANG; QU ZHANG; JUN-XING HUANG; ZHENG-DONG WU; XIN-CHEN SUN; SHENG-BIN DAI
- Abstract
The aim of the present study was to investigate the radiosensitization effect of triciribine (TCN) on human esophageal squamous cell carcinoma (ESCC) in normoxia or hypoxia and its mechanism. The cytotoxicity and radiosensitization mechanism of TCN were investigated by Cell Counting Kit 8, clonogenic assay, flow cytometry, western blotting (WB) and immunofluorescence staining of phosphohistone H2A.X, Ser139 (γ-H2AX) in ESCC in vitro, while the protein expression levels of AKT, phosphorylated (p)-AKT, hypoxia-inducible factor (HIF)-1α and vascular endothelial growth factor (VEGF) were evaluated by WB in vivo. The cytotoxicity of TCN was dose dependent. Upon exposure to TCN, ESCC cells in hypoxia treated with 4-Gy radiotherapy exhibited an evidently higher apoptotic rate than cells subjected to other treatments. TCN could significantly inhibit the protein expression of p-AKT, HIF-1α and VEGF in vitro and in vivo. The present results suggested that TCN can effectively inhibit AKT, p-AKT, HIF-1α and VEGF, thus conferring radiosensitivity to ESCC in vitro and vivo. TCN is considered as an adjuvant in radiotherapy of ESCC in clinical application.
- Subjects
PROTEIN kinase B; ANTINEOPLASTIC agents; TREATMENT of esophageal cancer; HYPOXIA-inducible factor 1; IN vitro studies
- Publication
Oncology Letters, 2017, Vol 13, Issue 2, p949
- ISSN
1792-1074
- Publication type
Article
- DOI
10.3892/ol.2016.5515